WHO vaccine-preventable diseases: monitoring system. 2016 global summary

Last updated 27-May-2016 (Data received as of 20-May-2016)
Next overall update Fall 2016
2015 data are provisionary
EPI mother and child logo         
Select a country

Development status: Developed economy GNI / capita (US$): 42'0001 Infant (under 12 months) mortality rate: 22
GDP / capita (US$): 36'4261 Child (under 5 years) mortality rate: 32

Population data in thousands3

  2015  2014  2013  2012  2011  2000  1990  1980 
Total population 126'573  126'795  126'985  127'140  127'253  125'715  122'249  115'912 
Births 1'033  1'041  1'050  1'059  1'069  1'155  1'280  1'605 
Surviving infants 1'031  1'039  1'048  1'057  1'067  1'151  1'274  1'593 
Pop. less than 5 years 5'269  5'302  5'336  5'367  5'387  5'858  6'430  8'425 
Pop. less than 15 years 16'272  16'406  16'550  16'695  16'822  18'385  22'389  27'311 
Female 15-49 years 26'077  26'323  26'541  26'733  26'904  29'155  31'194  30'403 

Number of reported cases

(Click for retrospective incidence data for Japan)
Diphtheria
ChartChart
  66 
Japanese encephalitis
ChartChart
 
Measles
ChartChart
  35  462  229  228  434  22'497  3'259  13'219 
Mumps
ChartChart
  81'046  46'340  40'999  71'549  137'060  132'659 
Pertussis
ChartChart
  2'675  2'066  1'663  4'087  4'395  3'787  583  5'033 
Polio*
ChartChart
 
Rubella
ChartChart
  163  320  14'359  2'353  369  3'120 
Rubella (CRS)
ChartChart
  31 
Tetanus (neonatal)
ChartChart
 
Tetanus (total)**
ChartChart
  120  126  127  116  111  90  47  50 
Yellow fever
ChartChart
 
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For desagregated data please click on this hyperlink: https://extranet.who.int/polis/public/CaseCount.aspx
it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).
** Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system.

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Japan)
Vaccine year result method % card seen                                                
BCG          84  93  93  95  94  96  85 
DTP1          99*  99*  99*  99*  99*  99* 
DTP3          96  99*  99*  99*  99*  85  87  60 
DTP4          91  99* 
IPV1          99* 
HepB_BD         
HepB3         
Hib3          99* 
JapEnc          99*  99*  99*  99*  61 
MCV1          96  98  95  96  94  96  66  69 
MCV2          93  94  93  92  92 
PCV1          99* 
PCV3          99* 
Pol3          99*  99*  99  99  96  99  90 
Rota1         
RotaC         
Rubella1          96  98  95  96  94 
TT2plus         
PAB         
VAD1         
YFV         
° indicates that more than 1 survey occurred that year.  * indicates the country reported above 100% coverage.

  Next update: Mid July 2016

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Japan)
BCG
ChartChart
  93  93  95  94  85 
DTP1
ChartChart
  99  99  99  99  88  96  82 
DTP3
ChartChart
  98  98  98  98  85  90  60 
HepB3
ChartChart
 
HepB_BD
ChartChart
 
Hib3
ChartChart
 
MCV1
ChartChart
  98  95  96  94  96  73  69 
MCV2
ChartChart
  94  93  92  92 
PCV3
ChartChart
 
Pol3
ChartChart
  99  99  99  96  98  90 
RotaC
ChartChart
 

Number of districts in the country 1'741  Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
 
   
/
|
|
\
Greater or equal to 90%
From 80 to 89%
From 50 to 79%
Less than 50%
Proportion of districts
not reporting DTP3 coverage
100
DTP3 reported coverageDTP3 reported coverage

Immunization Schedule (2015 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
BCG 1 year; Yes
DT 11 years; Yes
DTaPIPV 3, 4.5, 6, 18 months; Yes
HIB 2, 3, 4 months; 1 year; Yes
HPV 13 years (x3); Yes
Influenza_Adult >= 65 years; Yes and adults with chronic illness
JE_Inactd 36, 37 months; 4, 9 years; Yes
MR 1-2, 5-7 years; Yes
Pneumo_conj 2, 3, 4 months; 1 year; Yes
Pneumo_ps 65 years; Yes
Varicella 12, 18 months; Yes

Immunizaton indicators

Indicator Expected answer 2015  2014  2013  2012  2011  2010  2009 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR No  No  No  No  No  No  No 
What years does the MYP cover? number              
Nº of districts with microplans that include activities to raise immunization coverage number              

System performance

Total Nº districts in country number 1'741  1'748  1'742  1'725  1'724   
Nº districts with measles (MCV1) coverage >=95% number NA             
% of districts with MCV1 coverage >=95% From 0 to 100%              

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND Yes  Yes  Yes  Yes  Yes     
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Finance

Immunization expenditure financed, using Government funds? From 0 to 100% NA             

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR Yes  Yes  Yes  Yes  Yes     

Sources

 1  "The 2013 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2013, data for 2012
 3  "United Nations, Population Division. The World Population Prospects - the 2015 revision". New York, 2016.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.